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Abstract
Background: The evidence base for the effectiveness of psychological interventions for patients with dissociative
non-epileptic seizures (DS) is currently extremely limited, although data from two small pilot randomised controlled
trials (RCTs), including from our group, suggest that Cognitive Behavioural Therapy (CBT) may be effective in
reducing DS occurrence and may improve aspects of psychological status and psychosocial functioning.
Methods/Design: The study is a multicentre, pragmatic parallel group RCT to evaluate the clinical and cost-effectiveness
of specifically-tailored CBT plus standardised medical care (SMC) vs SMC alone in reducing DS frequency and improving
psychological and health-related outcomes. In the initial screening phase, patients with DS will receive their diagnosis
from a neurologist/epilepsy specialist. If patients are eligible and interested following the provision of study information
and a booklet about DS, they will consent to provide demographic information and fortnightly data about their
seizures, and agree to see a psychiatrist three months later. We aim to recruit ~500 patients to this screening stage.
After a review three months later by a psychiatrist, those patients who have continued to have DS in the previous
eight weeks and who meet further eligibility criteria will be told about the trial comparing CBT + SMC vs SMC alone.
If they are interested in participating, they will be given a further booklet on DS and study information. A research
worker will see them to obtain their informed consent to take part in the RCT. We aim to randomise 298 people
(149 to each arm). In addition to a baseline assessment, data will be collected at 6 and 12 months post randomisation.
Our primary outcome is monthly seizure frequency in the preceding month. Secondary outcomes include seizure
severity, measures of seizure freedom and reduction, psychological distress and psychosocial functioning, quality of life,
health service use, cost effectiveness and adverse events. We will include a nested qualitative study to evaluate participants’
views of the intervention and factors that acted as facilitators and barriers to participation.
Discussion: This study will be the first adequately powered evaluation of CBT for this patient group and offers the
potential to provide an evidence base for treating this patient group.
Trial registration: Current Controlled Trials ISRCTN05681227
ClinicalTrials.gov NCT02325544
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Background
Dissociative seizures (DS) superficially resemble epileptic
seizures or syncope but are not associated with ictal
electroencephalographic (EEG) discharges. They are
episodes of impaired self-control associated with a range
of motor, sensory, and mental manifestations. They are
one of the three common causes of Transient Loss of
Consciousness [1]. Other names for these phenomena in-
clude ‘psychogenic non-epileptic seizures’, ‘Non-Epileptic
Attack Disorder’ (NEAD), ‘non-epileptic seizures’, ‘func-
tional seizures’and the more pejorative ‘pseudoseizures’, to
name but a few. Approximately 12-20 % of patients seen
in epilepsy clinics may have DS [2] and such patients
present a diagnostic and management challenge. Recent
incidence estimates are 4.9/100,000/year [3]. Patients may
previously have been misdiagnosed and treated for epi-
lepsy; arrival at the correct diagnosis may take many years
[4]. Long-term outcome (chronic disability and welfare
dependence) has been noted to be poor in about 70 % of
patients [5]. The vast majority of patients with DS are
thought to have symptoms that are not deliberately
generated. Therefore, they would receive diagnoses of
somatoform disorder, conversion disorder, functional
neurological symptom disorder or dissociative disorder
under current classification systems [6–8].
DS are associated with high rates of psychiatric comor-
bidity (e.g. anxiety, depression, maladaptive personality
traits and post-traumatic stress disorder) (e.g. [9]). Pa-
tients with DS are also vulnerable to other functional
somatic symptoms such as chronic pain or other func-
tional neurological symptoms [10] and have a slightly
raised risk of non-seizure-related mortality [11]. They
may undergo unnecessary, costly and potentially harmful
tests and interventions and may sustain injuries during
their seizures. Quality of life (QoL) is lower than in
patients with epilepsy (e.g. [12]) and QoL correlates with
depression and somatic symptoms. Patients’ lifestyles
can be severely restricted through fear of having seizures
and high levels of avoidance behaviour [13, 14]. Patients
may be taking anti-epileptic drugs (AEDs) unnecessarily,
with associated risks for women of childbearing age. A
US study [15] evaluated the six-year cost pre-diagnosis to
be in excess of $25,000/patient (approximately €23,587)
and US lifetime costs were estimated at $110–920 m
(approximately (€103.8–868 m). In Ireland, [16] the aver-
age annual cost per person with undiagnosed DS was
calculated to be €5429.30 (i.e. approximately $5755),
assuming that the average time taken to reach a diagnosis
was five years. After correct diagnosis, a reduction in
medical service use with attendant cost reductions may
follow (e.g., [17, 18]).
Whilst psychotherapy is currently viewed as the treat-
ment of choice [19], the evidence for its effectiveness
is extremely limited [20–23]. The limited evidence to
support the use of psychotherapy for patients with DS
has come from a number of small uncontrolled studies
and pilot RCTs [24, 25] which suggest the potential effi-
cacy of Cognitive Behavioural Therapy (CBT). Our group’s
manualised CBT treatment for DS has, in a pilot RCT
[24], shown the potential to reduce DS frequency com-
pared to standard medical care. In that study, 66 patients
with DS were randomized to receive either CBT (plus
standard medical care) or standard medical care alone.
The primary outcome was seizure frequency at end of
treatment and at 6-month follow-up. In an intention-to-
treat analysis, seizure reduction following CBT was super-
ior at treatment end (group x time interaction p <0.0001).
At follow-up, there was a trend for the CBT group to be
more likely to have experienced 3 months of seizure
freedom (odds ratio 3.125, p = 0.086). Both treatments led
to some improvement in psychosocial functioning.
The lack of a clear evidence base is reflected in the
extremely variable care provision for DS patients in the
UK, with currently no rational basis on which to decide
whether psychotherapy and which type should be recom-
mended for this patient group. A survey of UK healthcare
professionals working with DS patients reflected this vari-
ability in that only one third of respondents indicated that
they could refer all their patients for psychotherapy, while
clinicians’ knowledge of what type (s) of psychotherapy
might be available and where was also mixed [19]. One
third of respondents indicated that fewer than half their
patients would be offered ≥1 psychotherapy session.
Despite an increasing acknowledgement of the interface
between neurology and psychiatry, neuropsychiatry care
pathways are relatively under-developed [26]. Indeed,
there is variable involvement of psychiatrists and psycho-
logists in the assessment and management of DS patients.
This is despite increased recognition that neuropsychiatric
disorders, such as DS, may cause distress to patients and
their carers, disability, burden and loss of productivity
[26]. More evidence would contribute to national and
local discussions about what treatments should be pro-
vided for patients with DS patients.
Our study follows MRC Guidelines for complex inter-
ventions [27]. We have already completed a proof of
principle RCT and obtained preliminary evidence of
efficacy [24]. Thus, the next step is to evaluate the clin-
ical and cost effectiveness of our intervention and assess
its generalisability in an adequately powered, pragmatic,
multi-centre RCT.
Aims and objectives
The overall aim of the CODES Trial is to evaluate the
clinical and cost effectiveness of specifically adapted
CBT (plus Standardised Medical Care-SMC) in compari-
son to SMC alone for outpatients with DS, within a
pragmatic, multi-centre RCT.
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Our primary objective is to evaluate the effectiveness
of CBT (plus SMC) compared to SMC alone in reducing
DS frequency (our primary outcome) at 12 months post
randomisation.
Our secondary objectives are to evaluate:
1) the effectiveness of CBT plus SMC compared to
SMC alone in reducing subjective DS severity and
disability and promoting seizure freedom, health-
related quality of life, and psychosocial and
psychological well-being at 12 months post
randomisation;
2) the effectiveness of CBT plus SMC compared to
SMC alone in reducing health service use at
12 months post randomisation;
3) the cost-effectiveness of CBT plus SMC compared
to SMC alone at 12 months post randomisation;
4) patients’ global change as a result of treatment
(Clinical Global Impression (CGI) [28] change score);
5) their satisfaction with treatment;
6) DS patients’ subjective experiences of CBT vs. SMC,
determined from qualitative interviews;
7) the treatment fidelity of our manualised DS-specific
CBT treatment across different therapists and its
implications for rollout in the NHS.
Methods and design
Trial design
The study is a multicentre, pragmatic, parallel group
randomised controlled trial (RCT) of CBT plus SMC vs
SMC alone. After an extended screening phase to iden-
tify eligible patients, those patients found to fulfil eligi-
bility criteria and who consent to the RCT are randomised
at a 1:1 ratio to either treatment arm. Patients will be
assessed at baseline (pre-randomisation) and sixmonths post
randomisation, with final outcome assessed at 12 months
post randomisation.
The study will take place in neurology services and
neuropsychiatry/mental health services in England,
Scotland and Wales. The current clinical neurology ser-
vices from which we will recruit patients for the screening
phase are those secondary and tertiary clinical services
seeing patients presenting with seizures that require diag-
nostic assessment and review; the clinical psychiatry ser-
vices from which we will subsequently consent patients
for the RCT are those that have interest and experience in
treating patients with DS. To date we have approval to
recruit participants from 25 neurology and 15 psychiatry
services.
Target population
The target population for this pragmatic trial is adult
outpatients with DS which persist following diagnosis by
neurologists/epilepsy specialists. Since our study comprises
more than one stage to ascertain eligibility, we describe
inclusion and exclusion criteria for each stage below. A
summary of the participant flow through the study is
shown in Fig. 1.
Recruitment
In order to randomise 298 patients (see justification
below) we need to identify a substantially larger pool of
DS patients in neurology clinics, since in addition to
other potential exclusion criteria, approximately 14 % of
DS patients will be seizure free three months post diag-
nosis [29]. In order to allow for ineligibility of patients
attending the psychiatry appointments, we envisage
needing to recruit 501 patients who meet eligibility in
the screening phase of the study.
Screening phase
Adults with DS will receive their diagnosis and an in-
formation leaflet on DS from a neurologist/epilepsy
specialist.
Participants will be included in the in the screening
phase if they:
 are adults (≥18 years) with DS that have continued
to occur within the previous 8 weeks and have been
confirmed by video EEG telemetry or, where not
achievable, clinical consensus; patients who have
chronic DS can be included if they have been seen
by the relevant Study Neurologist who has reviewed
their diagnosis and communicated this to them
according to the Study protocol;
 have no documented history of intellectual
disabilities;
 are able to complete seizure diaries and
questionnaires;
 are willing to complete seizure diaries regularly and
undergo psychiatric assessment 3 months after DS
diagnosis;
 are able to give written informed consent.
Participants will be excluded from the screening phase
if they:
 have a diagnosis of current epileptic seizures as well
as DS (where current is defined as an epileptic
seizure within the previous year). Patients with both
DS and ES have been included in small studies
(e.g. [30, 31]) but there is no method for verifying
that patients can accurately differentiate between
epileptic seizures and DS;
 are unable to keep seizure records or complete
questionnaires independently;
 meet DSM-IV [6] criteria for current drug/alcohol
dependence;
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Patients given dissociative
seizure (DS) diagnosis;
screening of eligibility
Not meeting eligibility criteria to
take part in further screening
Not wanting to take part
Not contactable
Withdrawn
Consenting participants who
meet eligibility criteria
Participants seen by
psychiatrist after 3 months
for assessment
Baseline assessment
Randomised
CBT + SMC SMC
6-month outcome
measures collected
12-month outcome
measures collected
Analysed
Withdrawn
Withdrawn
6-month outcome
measures collected
12-month outcome
measures collected
Analysed
Withdrawn
Withdrawn
Withdrawn
Not meeting eligibility criteria to
take part in RCT
Phase 1
Phase 2
Withdrawn
Fig. 1 Study flowchart: phase 1 = initial screening phase following diagnosis in neurology/specialist epilepsy services of identified patients; phase
2 = further screening following psychiatric assessment, baseline assessment, randomisation, treatment and follow-up; CBT = Cognitive Behavioural
Therapy; SMC = Standardised medical care
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 have insufficient command of English to later
undergo CBT or complete questionnaires without
an interpreter. Reasons for this include the need to
self-rate secondary outcomes using scales not
validated for non-English speaking populations, the
considerable cost and uncertainty of being able
reliably to engage sufficiently competent interpreters,
and the need to demonstrate the delivery of therapy
in terms of competence of therapists and adherence
to the therapy manual;
 are currently having CBT for another disorder, if
this will not have ended by the time that the
psychiatric assessment takes place;
 have previously undergone a CBT-based treatment
for dissociative seizures at a trial participating
centre.
If patients are deemed eligible for the screening stage
of the study they will be given study information and, if
interested, will be contacted by phone and/or letter by
a research worker. Following further eligibility checks
against the above criteria and explanation of the study
they will then be consented to the screening phase of
the study. In addition to the provision of demographic
data, participants’ DS seizure occurrence (in terms of
self-reported frequency and severity) will be monitored
fortnightly using seizure diary completion. Data will be
collected by a research worker by phone, email, text or
post, depending on the participant’s preference.
Three months after receiving their diagnosis of DS,
those meeting eligibility criteria so far will be reviewed
by a liaison psychiatrist or neuropsychiatrist with an
interest and expertise in DS, to carry out the final screen
for eligibility for the RCT.
Participants will be included in the in the RCT if at
the psychiatrist assessment visit and pre-randomisation:
 they are adults (≥18 years, no upper age limit) with
DS, initially recruited at point of diagnosis;
 they are willing to continue to complete seizure
diaries and questionnaires;
 they have provided regular seizure frequency data
following receipt of DS diagnosis;
 they are willing to attend weekly/fortnightly sessions
if randomised to CBT;
 they and the clinician consider that randomisation is
acceptable in the participant’s case;
 they are able to give written informed consent.
Participants will be excluded from the RCT if, at the
psychiatric assessment visit and pre-randomisation, they:
 are having current epileptic seizures as well as DS,
for reasons given above;
 have not had any DS in the 8 weeks prior to the
psychiatric assessment;
 have previously undergone a CBT-based treatment
for dissociative seizures at a trial participating
centre;
 are currently having CBT for another disorder;
 have active psychosis;
 meet DSM-IV [6] criteria for current drug/alcohol
dependence; this may exacerbate symptoms/alter
psychiatric state and health service use and affect
recording of seizures;
 have current benzodiazepine use exceeding the
equivalent of 10 mg diazepam/day;
 are thought to be at imminent risk of self-harm,
after (neuro) psychiatric assessment or structured
psychiatric assessment by the Research Worker with
the MINI, followed by consultation with the
psychiatrist.
 have a known diagnosis of Factitious Disorder.
The psychiatrist will go through the diagnosis again,
undertake a clinical assessment and provide them with a
further, more extensive information booklet on DS.
Those patients who have continued to experience DS in
the previous eight weeks and who meet the further study
criteria listed above will, with their agreement be con-
tacted by a research worker and then, if willing, consent
to take part in the trial, undergo a baseline assessment
and then be randomised to receive either 12 sessions of
CBT (plus a booster session) plus SMC or SMC alone.
Interventions
Standardised medical care (SMC)
While the provision of standard medical care to DS pa-
tients in the UK is variable [19], different specialities
contribute to standard care in specific ways. Through
the development of a protocol and the development of
new as well as use of existing materials, we have estab-
lished key approaches to the delivery of what is best con-
sidered here as Standardised Medical Care (SMC). This
will contain elements documented elsewhere and shown
to be achievable and acceptable to patients [29]. This ap-
proach, involving the provision of a prompt sheet, de-
tailed leaflet for clinicians and briefing sessions for
medical staff has been shown to work in other studies
[29]. The key elements of SMC are described below.
SMC will be provided to study patients by neurologists
and psychiatrists. Neurologists will generally undertake
the assessment and investigation and then make and
deliver the diagnosis, which is the first step in the treat-
ment pathway [22]. Psychiatrists will provide further
assessment of aetiological and maintenance factors,
assess and treat complex co-morbidity and give routine
advice on seizure management and adaptation but
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without using CBT techniques. As part of SMC we have
devised two information booklets about DS to be given
to patients, to supplement the information given to them
during their clinical appointments by the neurologists and
psychiatrists. These booklets have been created with con-
tributions from service users and a Hospital Information
Officer to increase ease of reading and are as follows:
1. Dissociative Seizures Factsheet (Neurology) is a
short booklet for neurologists to give to patients
when they deliver the diagnosis.
2. Dissociative Seizures Factsheet (Psychiatry) is more
detailed written information to supplement SMC
psychiatric assessment and treatment. The aim is for
this to be given to the patient at the time of the
initial psychiatric assessment.
Neurologists’ delivery of SMC
Neurologists will be expected to assess the patient in
their usual way to determine the nature of the patient’s
seizures. In some cases it will be possible to make a se-
cure diagnosis on the basis of the history, witness history
and physical assessment. In other cases mobile phone
footage, EEG or video EEG may be required to make the
diagnosis. Where available and practical an EEG with
concurrent video is the most reliable way to make the
diagnosis but it is not mandatory. Likewise, neuroimag-
ing is not mandatory and it is anticipated that this will
be carried out only according to clinical need. Where
video EEG telemetry is not available, we will accept a
consensus diagnosis that either involves the agreement
between two neurologists in the clinical service dealing
with the patient or between the study neurologist and
one neurologist within the project team.
Neurologists will not be expected to carry out a stan-
dardised psychiatric assessment. However, as with all pa-
tients attending a neurological service, if there are
clearly recognisable psychiatric risks related to self-
harm, harm of others or psychosis the neurologist will
refer to the relevant psychiatric services, or ask the pa-
tient’s general practitioner (GP) to do so.
All neurologists will be expected to give patients a
copy of an information booklet about Dissociative
Seizures (see above). In addition to information about DS
this will include direction to self-help information (e.g.
www.nonepilepticattacks.info, www.neurosymptoms.org).
The neurologist will be expected to provide the follo-
wing information:
1) An explanation of what DS are: i) i.e. provide the
patient with a diagnostic label; ii) explain that the
patients do not have epilepsy and why, drawing
particular attention to positive aspects of the
diagnosis (e.g. that this is not epilepsy) and
explaining why tests are confirmatory of the
diagnosis; iii) explain that the person’s attacks are
genuine and they are not suspected of “putting on”
or ‘imagining’ the attacks; iv) explain that the
disorder is common; v) explain that the condition is
potentially reversible.
2) An explanation of the mechanism underlying DS:
We allow for the possibility that neurologists may
wish to talk about the mechanism of the attacks
being a ‘trance-like’ state called dissociation, similar
to that seen in hypnosis. Individual explanations will
vary according to the patient’s presentation. We
advise the neurologist against using any explanation
that leaves the patient thinking that the doctor
does not believe them or thinks they are just
‘making it up’.
3) An explanation for referral to a psychiatrist: We
recommend that the neurologist emphasises the
following issues to the patient in discussing the
referral to a psychiatrist and encourages them to
attend: i) the doctor may be a psychiatrist but
they will not think the patient is ‘crazy’; ii) the
psychiatrist knows about DS and has successfully
helped other patients with the problem;
iii) psychosocial factors are often important in
understanding DS and part of the reason for referral
is to explore this further; iv) to assess factors that
might be maintaining the attacks.
There are other aspects of the initial neurological con-
sultation that may vary according to the patient but
could involve: i) explaining that antiepileptic drugs do
not help DS, can have serious long-term side effects and
should be withdrawn gradually; ii) explaining that talking
treatments may be helpful for some people but the evi-
dence is currently uncertain as to whether it is worth-
while; iii) providing explanations to family and friends
about the diagnosis, and what to do when the patient
has an attack; iv) providing general information about dis-
traction techniques; and v) discussing driving regulations.
Further neurology follow-up
We are recommending that the neurologists offer at
least one further neurology follow-up visit (although
fewer or more are allowable) which may typically cover
the following topics: i) overall general review of progress;
ii) checking the patient’s understanding of the diagnosis
and explaining it again if necessary; iii) supervision of
AED withdrawal; iv) management of any comorbid phy-
sical conditions; reassessment of major psychiatric risk
such as self-harm or psychosis; v) recommendations for
antidepressant or anti-anxiety medication prior to the
first visit with the psychiatrist if clinically indicated; and
vi) completion of forms about driving or from the
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Department of Work and Pensions if requested by those
agencies.
Psychiatrists’ delivery of SMC
Psychiatrists’ provision of SMC of patients begins after
diagnosis with an outpatient appointment as close as pos-
sible to three months after the neurological assessment.
The initial clinical psychiatric assessment will include
the following components. It should include: i) a reite-
ration of all of the points covered by the neurologist at
diagnosis, including checking the patient has received
the information booklet about Dissociative Seizures that
was delivered by the Neurologist and direction to self-
help information; ii) provision of a more detailed booklet
“Dissociative Seizures Factsheet (Psychiatry); iii) acknow-
ledgement of fears about a psychiatric label; iv) clinical
assessment of relevant axis 1 (e.g. depression, anxiety)
and axis 2 (personality disorder traits) psychiatric disor-
ders, including an assessment of the risk of self-harm/
suicide; v) explanation and treatment of any psychiatric
comorbidity which may include provision of psycho-
pharmacological treatment (e.g., antidepressants) or ge-
neral treatment as required; vi) explanation of any other
functional somatic symptoms, general advice about man-
agement and referral to physiotherapy if appropriate for
mobility problems; vii) discussion of factors emerging
from the clinical history that seem to have aetiological
significance: relevance of predisposing, precipitating and
perpetuating factors in their case if apparent; viii) pro-
vision of general information about any warning symp-
toms and distraction but specific techniques will not be
discussed so that this does not become therapy; and ix)
liaison with other mental health professionals involved
in the patient’s case as appropriate but referrals for other
psychotherapeutic input (including use of CBT tech-
niques) specifically for DS will not be made. The em-
phasis should be on psycho-education and management
of comorbid psychiatric conditions in the normal way.
The session may also include involvement of family or
friends in the above steps as required; encouragement in
social activities; return to college/work as appropriate
with any necessary liaison with work/school/college to
explain the disorder and assist with the correct manage-
ment of DS in these environments if appropriate; com-
pletion of forms about driving or the Department of
Work and Pensions if requested by those agencies.
Further SMC by psychiatrists will include support,
consideration of psychiatric comorbidities and any asso-
ciated drug treatment and general review but CBT tech-
niques for DS will not be discussed.
Neurologists and psychiatrists will be provided with a
prompt sheet containing the essential information to be
covered during sessions, an expanded description of
information they might provide to patients, a set of
Frequently Asked Questions and access to the secure
section of the study website (www.codestrial.org). On
the website they can access trial materials and videos
demonstrating delivery of the diagnosis by neurologists
and explaining randomisation.
Despite some local variation (due to factors such as
commissioning differences and clinicians’ preferences),
following the initial neurology assessment and the psy-
chiatric assessment we anticipate up to two neurology
SMC sessions and three-to-four psychiatry SMC ses-
sions. However, due to the pragmatic nature of the study
we are not prescribing the number of sessions.
Cognitive Behavioural Therapy (CBT)
CBT will be delivered over 12 sessions (each approxi-
mately one hour in length) over a 4–5 month period, with
one booster session at 9 months post randomisation.
Our model has been developed from a single case study
[32], trialled in an open label study [33] and then in a pilot
RCT [24]. Thus, based on our pilot RCT [24] we will as-
sess a 12-session (plus one booster session) package of
CBT specifically modified for treating DS. This has been
described [34] and tested by our group [24, 33].
The model is based on Lang’s [35] two-process fear
escape-avoidance model and conceptualises DS as dis-
sociative responses to cues (cognitive/emotional/physio-
logical or environmental) that may (but not in all cases)
have been associated in some cases with distressing or
life-threatening experiences, such as abuse or trauma at
an earlier stage in the person’s life, or following events
such as panic attacks or syncope and which have previ-
ously produced intolerable feelings of fear and/or
distress [34]. There are essentially five stages to the
treatment; engagement and rationale giving; teaching
and use of seizure control techniques; reducing avoi-
dance using exposure techniques; dealing with seizure-
related cognitions, facilitating the processing of emotions
and where appropriate trauma; and relapse prevention.
Thus, treatment includes helping the patient to: i) de-
velop a more coherent understanding of their DS; ii) de-
velop an understanding of the interrelationship between
cognitive, emotional, physiological and behavioural as-
pects of their DS; iii) understand factors maintaining the
occurrence of their DS; iv) learn how to interrupt the
behavioural, cognitive or physiological responses occur-
ring prior to or at the start of the seizures; v) engage in
previously avoided activities, address negative thoughts
and illness attributions maintaining seizures; vi) deal
with previous traumatic experiences, anxiety, low mood
or low self-esteem if present, and vii) become more
independent and understand the role of significant
others in their illness.
Sessions include typical CBT techniques and here, im-
portantly, completion of seizure diaries. Although our
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treatment manual outlines the content of the 12 sessions
in detail and provides hand-outs to be given to patients
that supplement the content of the therapy sessions, the
structure allows the treatment to be formulation-based
so that particular issues raised in therapy that might
be maintaining seizure occurrence (e.g. trauma-related
issues) can be addressed.
Sessions will be delivered at participating National
Health Service (NHS) sites. Attendance at CBT sessions
will be monitored, as will reasons for rescheduling the
sessions or for non-attendance. We will also record the
occurrence of DS during sessions that lead to disruption
of the session or injury. Therapists will rate patients’
completion of homework tasks and adherence to the
therapeutic model, on a sessional basis. If DS cease early
in treatment we will encourage continued attendance by
patients at sessions to address other significant aspects
of their presentation and to focus on relapse prevention.
The CBT will be delivered by CBT therapists (health
professionals, i.e. clinical psychologists/nurse therapists
or other professions allied to medicine-already trained in
CBT). They will be trained to deliver CBT for DS. Before
treating any trial patients, therapists will attend a three-
day workshop, specifically focusing on DS. The work-
shops will include DS-specific knowledge and skills.
Therapists will receive a combination of group super-
vision, four-to-six weekly and, where required, individual
supervision. With participants’ consent, all CBT sessions
will be audio-recorded. Some recordings will be used by
supervisors to provide feedback to therapists to ensure
adherence to the treatment model and specific treatment
approach. Any significant deviations from the manual
will be noted and fed back to the therapist. By adopting
such an approach our experience from other illnesses
suggests we can achieve expected treatment outcomes
and have very little therapist effect [36]. We will also use
the audio recordings to rate therapist competence, thera-
peutic alliance and adherence to the manualised therapy.
Outcome measures
Our primary evaluation of treatment is at 12 months
post-randomisation. However, we will also collect out-
come measures at 6 months post randomisation and
include these in our analyses.
Our primary outcome measure is monthly DS fre-
quency operationalised as seizure occurrence over the
previous four weeks. This is a discrete variable that com-
prises a count of seizures and therefore will reflect all
participants’ outcomes, whether they improve or not
during the study. Seizure frequency has been used as an
outcome measure in other studies of psychological inter-
ventions for DS (e.g. [24, 25, 30, 37, 38]). This will be
recorded by patients in seizure diaries, as has been done
in other studies of psychotherapy for DS. We will collect
seizure frequency data from the patients every two
weeks by whichever means they find acceptable (diaries,
text/phone/online). We will also request an overall
self-report estimate of DS frequency in the previous four
weeks from participants at baseline and the two follow-
up time points, to allow for missing diary data.
Our study seeks to evaluate the effectiveness and cost-
effectiveness of CBT+ SMC vs SMC alone in a number
of domains. Thus we have selected a range of clinical
and economic secondary outcome measures. These are
listed in Table 1. In view, however, of the likelihood of
psychiatric comorbidities moderating outcome in this
patient group, we also include at baseline a screening
measure of personality disorder, the Standardised Assess-
ment of Personality Abbreviated Scale, Self Report version
(SAPAS-SR) [39, 40] and a structured psychiatric scree-
ning instrument (the Mini International Neuropsychiatric
Interview; MINI v6.0 [41]); the prerandomisation assess-
ment will also include a single item measure of treatment
preference and a measure of expectations of treatment
outcome, both of which may also moderate outcome.
Other baseline data
We will describe the target population in a number of
ways. Demographic information (including age, gender,
relationship status, presence/absence of dependants
and/or a carer, ethnicity, postcode to evaluate Indices of
Multiple Deprivation, employment status, receipt of
state benefits, previous medical help sought for a mental
health problem, previous diagnosis of epilepsy and
current receipt of anti-epileptic drugs) will be collected
at the beginning of the screening phase. This will be
supplemented with information on self-reported pre-
existing medical conditions at the pre-randomisation
assessment so that reports of any newly-diagnosed
reported medical conditions or symptoms following
randomisation can be compared to these in order to
identify adverse events. Information on potential ad-
verse events will be collected systematically at 6 and 12
months post randomisation by the research workers.
We will also record demographic data and the qualifica-
tions and clinical experience of the neurologists, psychi-
atrists and therapists in the study.
As indicated in Table 1, we will investigate potential
mediators of the treatment effect by evaluating re-
sponses at baseline and the 6 and 12 month follow-up
time points on the Beliefs About Emotions Scale [42],
three locally-developed questions to measure avoidance
of people, places and activities due to DS, and a single
item scale for participants to measure their confidence
in the treatment they have received; we will investigate
whether a further item rating their confidence in their
diagnosis of DS may act as a moderator and/or mediator
of the treatment effect.
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Table 1 Primary and secondary outcome measures and times of data collection
Outcome variable/domain Standardised measure/other Putative moderators or
mediators of treatment
effects on clinical outcome
Clinical/
economic
outcomes
TO T1 T2
PRIMARY OUTCOME
Seizure frequency Seizure diary and self-report X X X X
SECONDARY OUTCOMES
Seizures Seizure severity; Two items measuring subjective severity (intensity)
and bothersomeness from the Seizure Severity Scale [53]
X X X X
Longest period of seizure freedom between T1 & T2; seizure diary
and self-report
X X
Seizure freedom for last 3 months of study; seizure diary and
self-report
X X
>50 % reduction in seizure frequency; seizure diary and self-report X X X
Informant’s rating of patient’s seizures; Rating as to whether
participant’s seizures are better/same/ worse or whether they are
seizure free
X X X
Health-related Quality of
Life (QoL)
SF-12v2 (12-item measure of health-related QoL) [50] X X X X
Psychosocial functioning Work and Social Adjustment Scale (5-item scale to measure
patients’ own perceptions of the impact of DS on their functioning
in terms of work, home management, social leisure and private
leisure activities, family and other relationships) [54]
X X X X
Avoidance of people, places and situations (3-item locally
devised scale)
Mediator X X X
Psychiatric symptoms and
psychological distress
GAD7 (7-item scale to measure anxiety) [55] X X X X
PHQ9 (9-item scale to measure depression) [56] X X X X
Modified PHQ15 (measure of other somatic symptoms) [57, 58] X X X X
CORE-10 (10-item scale; general measure of psychological distress
including risk) [59]
X X X X
12-item Beliefs About Emotions Scale [42] Mediator X X X
Clinical impression of
improvement
Clinical Global Impression (CGI) [28] Change score X X X
Clinical Global Impression (CGI) [28] Change score rated by
clinician (psychiatrist or neurologist)
X X
Clinical Global Impression (CGI) [28] Change score rated by CBT
therapist at end of session 12 of CBT
X
Satisfaction with treatment
and beliefs relating to
diagnosis and treatment
Single item measure of satisfaction with treatment X X X
Belief in diagnosis of DS (single item; 11 point scale) Mediator and/or
moderator
X X X
Belief in having been given the correct treatment (single item;
11 point scale)
Mediator X X X
Health economics Client Service Receipt Inventory [46]: Formal and informal health
service use
X X X X
EQ-5D-5L (5-item, 5 level measure) [49] X X X X
Linkage data setsa from Health and Social Care Information Centre
(Hospital Episode Statistics) eDRIS (NHS National Services Scotland
Information Services Division (ISD) and NHS Wales Informatics
Service
X X X X
T0 = Baseline (prerandomisation) (face to face); T1 = 6 month follow-up (postal); T2 = 12 month follow-up (face-to face)
aAll data sought electronically
Goldstein et al. BMC Neurology  (2015) 15:98 Page 9 of 13
Sample size calculation
We based our power calculation on the effect size ob-
tained in our pilot RCT study [24]. This data represented
the largest study of this kind to date and importantly
included a control group. Our previous pilot trial’s
analysis, which controlled for pre-randomisation seizure
frequency, reported a standardised effect size for the
reduction in seizure frequency under CBT compared to
SMC at the end of CBT treatment of Cohen’s d = 0.75
(log scale). Our previous study also detected a more
conservative and moderate effect size of Cohen’s d = 0.42
on the log-scale at a follow-up time more directly com-
parable to the current 12-month post randomisation point
(median seizure frequency in the CBT group: 12 at pre-
randomisation, 1.5 at follow-up; median frequency in the
SMC group: 8 at pre-randomisation, 5 at follow-up). We
consider this effect to be clinically important and therefore
base our power calculation on this moderate effect size.
To detect an effect of d = 0.42 with 90 % power using a
2-sided t-test for log-frequencies at the 5 % significance
level, we need 121 participants/group. The sample size
must be inflated to allow for potential therapist effects
within the CBT group, since each therapist will most likely
treat several patients. Based on a typical therapist intra-
class correlation coefficient of 0.02 [43] and 15 therapists
delivering CBT (average workload 10 patients/therapist),
149 participants are needed per arm to achieve 92.6 %
power. We will record pre-randomisation seizure frequen-
cies and include this information as a covariate in the ana-
lysis model. This will increase the precision of our future
intervention effect estimate. To account for this precision
gain and the subsequent reduction in sample size require-
ment, we can apply a deflation factor to the estimated
sample size [44]. We calculated the size of this deflation
factor as 0.8367 based on a correlation of r = 0.42 between
pre-randomisation and follow-up in DS frequencies [24].
Finally, in our pilot RCT, 7/66 patients were entirely lost
at follow-up. We therefore need to inflate the sample size
allowing for a more conservative rate of 17 % attrition at
12-month follow-up. Our final randomisation target is
298 participants (149 per arm).
Randomisation and concealment
Randomisation will be carried out by the King’s Clinical
Trials Unit (KCTU: www.ctu.co.uk) based at the Insti-
tute of Psychiatry, Psychology and Neuroscience, using a
web-based system. Randomisation takes place once par-
ticipants have consented to take part in the trial and
baseline assessments have been undertaken. The unit of
randomisation will be the individual participant. Strati-
fied randomisation with randomly varying block sizes
will be used to ensure 1:1 allocation within each of the
locations of the neuro/liaison psychiatry clinics from
which DS patients are recruited. Allocation will be
concealed from the research workers who undertake
trial data collection, and also from the trial statistician.
The Trial Manager will receive notification of the alloca-
tion so that therapists can be informed that they need to
arrange to see those participants requiring CBT. We will
require research workers to indicate if they have become
unblinded and when this occurred, so that outcome as-
sessments can be undertaken by blinded assessors.
Statistical analysis
Statistical analyses of the primary and secondary out-
comes will be conducted after the database has been
locked, with no interim analyses. All analyses will adopt
the intention to treat principle. Descriptive statistics will
describe the characteristics of the initial pool of patients
in the screening phase, and also those entering the RCT.
For the primary seizure frequency outcome, treatment
effectiveness will be assessed by estimating the incidence
rate ratio (IRR), comparing the CBT + SMC and SMC
arms at the 12-month follow-up time point. Generalised
linear mixed modelling (GLMM) assuming a Poisson
distribution, a log-link and allowing for possible overdis-
persion will provide this estimate. The dependent vari-
able of this analysis model will be seizure frequency at
6- and 12 months post randomisation. The explanatory
variables will be baseline seizure frequency, randomisation
stratifier (liaison/neuropsychiatry clinics), and trial arm,
time (6 or 12 months post-randomisation) and trial arm x
time interaction. All the available post-randomisation data
is modelled simultaneously to gain precision. The model
includes the interaction term to allow for time-varying
treatment effects. The model also contains participant-
varying random intercepts to account for the correlation
between the two repeated measures, and will consider in-
cluding random effects to account for effects of the doctor
delivering SMC and therapist-varying intercepts in the
CBT arm to account for therapist effects. The models are
estimated using maximum likelihood analysis and will
allow for missing outcome data under the missing at
random (MAR) assumption. The effect of departures from
this assumption on results will be assessed using sensi-
tivity analyses [45]. Analyses of secondary outcomes will
use a similar approach (for example, continuous outcomes
such as quality of life will be analysed using a linear mixed
model).
Cost effectiveness analysis
We will undertake a cost-effectiveness analysis from a
(i) health and social care and (ii) societal perspective
(including lost productivity and informal care). The
number and duration of CBT sessions will be centrally
recorded and other service utilisation will be recorded
with the Client Service Receipt Inventory [46] question-
naire at baseline, and at 6-and 12-month follow-ups.
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This will include primary and secondary care contacts,
social care use, care from family members and medica-
tion. We will also record lost work time. Information
from Hospital Episode Statistics will also be used to esti-
mate hospital use.
Intervention costs for the CBT sessions will be based
on factors such as salaries, overheads, training and
supervision. Unit costs for other services will be ob-
tained from national sources [47, 48]. Costs of lost work
and informal care will be based on average wage rates
but with alternative values used in sensitivity analyses.
Costs will be combined with the primary outcome mea-
sure (change in DS frequency) and also QALYs generated
from the EQ-5D-5L [49] using area-under-the-curve
methods. In sensitivity analyses we will use the SF-6D,
generated from the SF-12v2 [50], to derive QALYs via an
algorithm developed by economists at the University of
Sheffield [51]. If the intervention is less expensive and
more effective than SMC then it will be ‘dominant’. If
it is more expensive and more effective, incremental
cost-effectiveness ratios will be constructed to show the
extra cost incurred to achieve a one-unit reduction in
DS frequency or one extra QALY. Uncertainty around
cost-effectiveness estimates will be explored using cost-
effectiveness planes (derived from incremental cost-
outcome pairs from 1000 bootstrapped resamples) and
cost-effectiveness acceptability curves (CEACs - derived
using the net benefit approach). In addition to the use
of the SF-6D, sensitivity analyses will also be conducted
around the costs of the intervention, informal care and
lost employment. There has been limited previous re-
search in this area and this trial will provide evidence
on the impact of CBT in DS patients over a one-year
follow-up.
Qualitative study
We will undertake a nested qualitative study to inves-
tigate the illness attributions, treatment preferences and
experiences of trial participants. In-depth interviews
with 20 patients selected across sites who have received
CBT + SMC and 10 who have only received SMC will be
undertaken to understand what they felt to be beneficial
in terms of the interventions, and what made it easy or
more difficult for them to take part. We will also enquire
about the extent to which they have been able to imple-
ment the content of the CBT, and their views of the
content of the therapy. We will include participants who
did not attend all the CBT sessions, as well as those who
did. The interviews will take place in participants’ homes
or will be office-based. The interviews will be digitally
recorded and transcribed. Thematic Framework Analysis
[52] will be carried out by at least two Research Workers
under the supervision of an experienced qualitative re-
searcher and rigour will be increased by them undertaking
independent coding, followed by discussion meetings to
agree a coding framework, to reduce bias in the interpre-
tation of themes. Triangulation of the findings from the
qualitative analysis with the results of the quantitative
outcome measures will increase understanding of the trial
process and may assist in understanding anomalies in
outcomes.
Data handling and monitoring
We will collect data on paper source data worksheets.
Data will then be entered onto the InferMed MACRO
online data entry system, on a study specific database
designed and hosted at the KCTU. The system is
compliant with Good Clinical Practice and FDA 21 CFR
Part 11. Randomisation and post-randomisation infor-
mation will be accessed directly by the trial statistician
using CTU systems.
In addition to a Trial Management Group (TMG), moni-
toring of the trial activities and recruitment will be under-
taken by the Trial Steering Committee (TSC) and the
DMEC. The DMEC will monitor recruitment into both
the initial screening (phase 1) and randomisation (phase 2)
stages of the trial on a monthly basis. Monitoring by the
study team, the Trial Manager and the KCTU will ensure
that the trial complies with Good Clinical Practice and
maintains scientific integrity. The Trial Manager will
monitor data collection procedures and undertake source
verification checking against the paper data records at
regular intervals.
We have developed a protocol for monitoring adverse
events during both the screening and RCT phases of the
study. While we may become aware of adverse events at
any stage of the study, research workers will specifically
enquire about these at the 6-and 12-month post ran-
domisation follow-up points. We anticipate a high rate
of these events, given the likely psychiatric comorbidity
in this patient group, but we will distinguish between
serious adverse events that are likely/unlikely to be due
to the intervention in the RCT phase of the study. At
the end of the study, three independent scrutineers, with
clinical experience of working with DS patients, will
assess whether events were serious or non-serious.
Discussion
To our knowledge this is the first adequately powered
randomised controlled trial of a psychological interven-
tion to treat DS, anywhere in the world. The study has
considerable challenges given the different care services
involved and the likely psychiatric comorbidity of pa-
tients, which may make study compliance difficult,
although the collaboration of a large number of clini-
cians and researchers with expertise in DS may facilitate
means to encourage compliance. The study is set in the
context of the UK NHS and if it yields a positive
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outcome in terms of clinical and cost effectiveness, it
will provide the opportunity for the NHS to commission
evidence-based care for this group of patients, for whom
the availability of care provision is currently notably
inconsistent.
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